First Time Loading...

Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 388.205 USD 0.28% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. [ Read More ]

The intrinsic value of one MEDP stock under the Base Case scenario is 284.944 USD. Compared to the current market price of 388.205 USD, Medpace Holdings Inc is Overvalued by 27%.

Key Points:
MEDP Intrinsic Value
Base Case
284.944 USD
Overvaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medpace Holdings Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MEDP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Medpace Holdings Inc

Provide an overview of the primary business activities
of Medpace Holdings Inc.

What unique competitive advantages
does Medpace Holdings Inc hold over its rivals?

What risks and challenges
does Medpace Holdings Inc face in the near future?

Has there been any significant insider trading activity
in Medpace Holdings Inc recently?

Summarize the latest earnings call
of Medpace Holdings Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medpace Holdings Inc.

Provide P/S
for Medpace Holdings Inc.

Provide P/E
for Medpace Holdings Inc.

Provide P/OCF
for Medpace Holdings Inc.

Provide P/FCFE
for Medpace Holdings Inc.

Provide P/B
for Medpace Holdings Inc.

Provide EV/S
for Medpace Holdings Inc.

Provide EV/GP
for Medpace Holdings Inc.

Provide EV/EBITDA
for Medpace Holdings Inc.

Provide EV/EBIT
for Medpace Holdings Inc.

Provide EV/OCF
for Medpace Holdings Inc.

Provide EV/FCFF
for Medpace Holdings Inc.

Provide EV/IC
for Medpace Holdings Inc.

Show me price targets
for Medpace Holdings Inc made by professional analysts.

What are the Revenue projections
for Medpace Holdings Inc?

How accurate were the past Revenue estimates
for Medpace Holdings Inc?

What are the Net Income projections
for Medpace Holdings Inc?

How accurate were the past Net Income estimates
for Medpace Holdings Inc?

What are the EPS projections
for Medpace Holdings Inc?

How accurate were the past EPS estimates
for Medpace Holdings Inc?

What are the EBIT projections
for Medpace Holdings Inc?

How accurate were the past EBIT estimates
for Medpace Holdings Inc?

Compare the revenue forecasts
for Medpace Holdings Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medpace Holdings Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medpace Holdings Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medpace Holdings Inc compared to its peers.

Compare the P/E ratios
of Medpace Holdings Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Medpace Holdings Inc with its peers.

Analyze the financial leverage
of Medpace Holdings Inc compared to its main competitors.

Show all profitability ratios
for Medpace Holdings Inc.

Provide ROE
for Medpace Holdings Inc.

Provide ROA
for Medpace Holdings Inc.

Provide ROIC
for Medpace Holdings Inc.

Provide ROCE
for Medpace Holdings Inc.

Provide Gross Margin
for Medpace Holdings Inc.

Provide Operating Margin
for Medpace Holdings Inc.

Provide Net Margin
for Medpace Holdings Inc.

Provide FCF Margin
for Medpace Holdings Inc.

Show all solvency ratios
for Medpace Holdings Inc.

Provide D/E Ratio
for Medpace Holdings Inc.

Provide D/A Ratio
for Medpace Holdings Inc.

Provide Interest Coverage Ratio
for Medpace Holdings Inc.

Provide Altman Z-Score Ratio
for Medpace Holdings Inc.

Provide Quick Ratio
for Medpace Holdings Inc.

Provide Current Ratio
for Medpace Holdings Inc.

Provide Cash Ratio
for Medpace Holdings Inc.

What is the historical Revenue growth
over the last 5 years for Medpace Holdings Inc?

What is the historical Net Income growth
over the last 5 years for Medpace Holdings Inc?

What is the current Free Cash Flow
of Medpace Holdings Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Medpace Holdings Inc

Current Assets 593.8m
Cash & Short-Term Investments 245.4m
Receivables 298.4m
Other Current Assets 50m
Non-Current Assets 1.1B
PP&E 265.4m
Intangibles 698.2m
Other Non-Current Assets 99.4m
Current Liabilities 925.1m
Accounts Payable 31.9m
Accrued Liabilities 315.3m
Other Current Liabilities 577.9m
Non-Current Liabilities 172.7m
Other Non-Current Liabilities 172.7m
Efficiency

Earnings Waterfall
Medpace Holdings Inc

Revenue
1.9B USD
Cost of Revenue
-1.4B USD
Gross Profit
524.5m USD
Operating Expenses
-187.7m USD
Operating Income
336.8m USD
Other Expenses
-54.2m USD
Net Income
282.6m USD

Free Cash Flow Analysis
Medpace Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MEDP Profitability Score
Profitability Due Diligence

Medpace Holdings Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional ROE
Exceptional 3-Years Revenue Growth
73/100
Profitability
Score

Medpace Holdings Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

MEDP Solvency Score
Solvency Due Diligence

Medpace Holdings Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
77/100
Solvency
Score

Medpace Holdings Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDP Price Targets Summary
Medpace Holdings Inc

Wall Street analysts forecast MEDP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDP is 423.504 USD with a low forecast of 343.4 USD and a high forecast of 504 USD.

Lowest
Price Target
343.4 USD
12% Downside
Average
Price Target
423.504 USD
9% Upside
Highest
Price Target
504 USD
30% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MEDP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MEDP Price
Medpace Holdings Inc

1M 1M
-1%
6M 6M
+64%
1Y 1Y
+99%
3Y 3Y
+116%
5Y 5Y
+590%
10Y 10Y
+1 297%
Annual Price Range
388.205
52w Low
187.26
52w High
413.31
Price Metrics
Average Annual Return 41.54%
Standard Deviation of Annual Returns 30.23%
Max Drawdown -9%
Shares Statistics
Market Capitalization 11.9B USD
Shares Outstanding 31 825 000
Percentage of Shares Shorted 4.59%

MEDP Return Decomposition
Main factors of price return

What is price return decomposition?

MEDP News

Other Videos

Company Profile

Medpace Holdings Inc Logo
Medpace Holdings Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

11.9B USD

Dividend Yield

0%

Description

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 4,500 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The firm's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Contact

OHIO
Cincinnati
5375 Medpace Way
+15135799911.0
http://investor.medpace.com/investor-overview

IPO

2016-08-11

Employees

4 500

Officers

Chairman & CEO
Dr. August James Troendle M.D.
President
Mr. Jesse J. Geiger BBA, CPA
CFO & Treasurer
Mr. Kevin M. Brady
Executive Vice President of Operations
Ms. Susan E. Burwig BSN, MA
Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Stephen P. Ewald J.D.
Chief Information Officer
Brandon Ebken
Show More
Associate Director of Investors Relations
Ms. Lauren Morris
Vice President of Business Development & Marketing
Mr. Todd Meyers
Senior Vice President of Commercial Operations & Clinical Pharmacology Unit
John T. Wynne MBA
Chief Medical Officer of Medical Department
Mr. Reinilde Heyrman M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MEDP stock?

The intrinsic value of one MEDP stock under the Base Case scenario is 284.944 USD.

Is MEDP stock undervalued or overvalued?

Compared to the current market price of 388.205 USD, Medpace Holdings Inc is Overvalued by 27%.